Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics

Award Number: R37CA297814
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/10/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2029

Group Awards By:

View Award Description

Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics - Infection with hepatitis B virus (HBV), is the most common risk factor for the development of hepatocellular carcinoma (HCC) worldwide. HBV infection can cause HCC before liver cirrhosis, thereby affecting younger persons. A recent study from our South American Liver Research Network (SALRN) found that HBV-related HCC occurs at earlier ages in Hispanics than HCC related to other liver diseases. This HBV complication is of particular concern as HCC occurs outside of the “standard” recommended age for starting HCC screening. Currently, individuals with HBV are advised to undergo ultrasonography of the liver every 6 months with the goal of “visually” identifying a tumor small enough that might be amenable to curative treatment. This visual screening approach has poor adherence due to a variety of issues, such as time commitment, and is dependent on the ultrasound operator expertise. We hypothesize that a non-visual screening approach with standardized immune-related blood biomarkers may be a sensible alternative approach. Our group recently identified a series of immune markers detected in serum of patients with hepatitis that were able to predict the future development of HCC, even when the cancer occurred two years later. In this project, we will investigate whether the hyper-immune environment, product of the continuous presence of the virus in the liver, could lead to further alterations in measurable immune analytes in serum so to predict early HCC development. Using our multinational on-going networks of SALRN and ESCALON in Latin America, we propose to cross-sectionally and prospectively evaluate peripheral immune variations in Hispanic HBV-infected individuals as markers to predict early HCC development. In Specific Aim 1, we will determine if novel immune signatures in the serum of persons with chronic HBV infection and hepatocellular carcinoma show differential expression compared to controls. We will evaluate a pre-defined panel of immune analytes via multiplex cytokine analysis comparing HBV- infected HCC cases with controls In Specific Aim 2, we will validate a novel immune signature in serum for identifying those who will progress to hepatocellular carcinoma in persons with chronic HBV infection. We will prospectively collect samples from HBV-infected Hispanics in two regions of high HBV prevalence in South America and validate our HCC-immune signature In Specific Aim 3, we will evaluate intrahepatic immune markers in HBV-infected livers at risk for HCC. We will use spatial genomics intersected with HBV staining in liver biopsies from Latin America to further understand the mechanisms behind immunomodulation of HBV-related HCC This study will provide innovative data that will impact Hispanic persons living with chronic HBV infection, seeking to create a new standard of care for liver cancer screening in this population.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $547,902 )
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Detection and Diagnosis Research	002	2	3/5/2026	SUPPLEMENT FOR EXPANSION	$45,431
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Detection and Diagnosis Research	000	2	3/3/2026	NON-COMPETING CONTINUATION	$416,887
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Detection and Diagnosis Research	001	2	3/4/2026	NON-COMPETING CONTINUATION	$0
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Detection and Diagnosis Research	003	2	3/6/2026	SUPPLEMENT FOR EXPANSION	$85,584
														Subtotal = $547,902

Issue Date FY: 2025 ( Subtotal = $580,238 )
2025	2025	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Cancer Detection and Diagnosis Research	000	1	1/10/2025	NEW	$580,238
														Subtotal = $580,238

Grand Total All Awards = $1,128,140

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics

Award Number: R37CA297814

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/10/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer